ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Hematologic Malignancies

Melanoma Risk Increased in CLL/SLL Patients

Results of a new study have indicated that the risk of developing melanoma may be almost doubled among survivors of chronic lymphocytic leukemia/small lymphocytic lymphoma who were treated with certain chemotherapeutic agents or who had specific immune-related medical conditions.

Hematologic Malignancies

Vietnam War veterans exposed to Agent Orange as part of Operation Ranch Hand were at double the risk for monoclonal gammopathy of undetermined significance, a precursor to multiple myeloma, according to results of a new study.

Combined treatment with lenalidomide/rituximab resulted in better clinical response in patients with recurrent follicular lymphoma than did lenalidomide alone.

Daratumumab, a monoclonal antibody that targets CD38, was safe and effective in patients with heavily pretreated and refractory multiple myeloma.

A complex high-dose combination therapy is tolerable and effective in patients with aggressive B-cell lymphoma that has spread to the central nervous system.

Continuous therapy resulted in delays in first and second progression compared with fixed-duration therapy in patients with newly diagnosed multiple myeloma.

Researchers combined clinical risk factors with mutation status from seven genes to improve prognostication for patients with follicular lymphoma.

Pages

Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.